KRAS and colorectal carcinoma: To this end, we measured cell viability by MTS assays and defined the lowest dose of each agent, ranging between IC20 and IC10, effective on both KRAS-mutated metastatic SW620 cells and CTSC#18, a CSC line derived from a CRC patient [30] (Table 1).